XORTX THERAPEUTICS INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 4.07 CAD | +12.43% |
|
0.00% | +40.34% |
| 04-22 | XORTX Therapeutics Announces Publication of Key Research in ADPKD in Peer-reviewed Journal | MT |
| 04-08 | XORTX Therapeutics Inc. Appoints Abigail Jenkins to the Board of Directors | CI |
| Sales 2024 * | - | Sales 2025 * | - | Capitalization | 4.37M 5.98M 350M |
|---|---|---|---|---|---|
| Net income 2024 * | - | Net income 2025 * | - | EV / Sales 2024 * | - |
| Net cash position 2024 * | - 0 0 | Net cash position 2025 * | - 0 0 | EV / Sales 2025 * | - |
| P/E ratio 2024 * |
-
| P/E ratio 2025 * |
-
| Employees | 3 |
| Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 95.92% |
More Fundamentals
* Assessed data
More news
More press releases
More news
| 1 day | +12.43% | ||
| Current month | -18.60% | ||
| 1 month | -20.51% | ||
| 3 months | +31.29% | ||
| 6 months | -3.78% | ||
| Current year | +40.34% |
1 week
3.42
4.17
1 month
3.425.32
Current year
2.909.35
1 year
2.659.99
3 years
2.6589.81
5 years
2.6589.81
10 years
2.6589.81
| Managers | Title | Age | Since |
|---|---|---|---|
Allen Davidoff
FOU | Founder | 64 | 08/01/18 |
Jim Fairbairn
DFI | Director of Finance/CFO | 65 | 05/11/18 |
Stephen Haworth
CTO | Chief Tech/Sci/R&D Officer | - | 30/06/21 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Paul van Damme
BRD | Director/Board Member | - | 24/01/18 |
Allen Davidoff
FOU | Founder | 64 | 08/01/18 |
| Chairman | 67 | 05/06/22 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 26/04/24 | 4.07 | +12.43% | 9,937 |
| 25/04/24 | 3.62 | -8.35% | 6,008 |
| 24/04/24 | 3.95 | 0.00% | 7,996 |
| 23/04/24 | 3.95 | -2.95% | 1,700 |
| 22/04/24 | 4.07 | 0.00% | 5,500 |
Delayed Quote Toronto S.E., April 26, 2024 at 08:59 pm
More quotes
XORTX Therapeutics Inc. is a Canada-based late-stage clinical pharmaceutical company. The Company develops therapies to treat progressive kidney disease modulated by aberrant purine and uric acid metabolism in orphan disease indications, such as autosomal dominant polycystic kidney disease (ADPKD), as well as type 2 diabetic nephropathy (T2DN) and fatty liver disease. It is working to advance its clinical development stage products that target aberrant purine metabolism and xanthine oxidase to decrease or inhibit production of uric acid. The Company has three product development programs: XRx-008, which is a program for the treatment of ADPKD; XRx-101, which is a program to treat acute kidney injury (AKI) associated with respiratory virus infection, AKI and associated health consequences, and XRx- 225, a program for the treatment of T2DN. The Company's XRx-008 program is designed for longer term stable chronic oral dosing of xanthine oxidase inhibitors.
Calendar
28/05/2024
- Q1 2024 Earnings Release (Projected)
Sell
Buy
Mean consensus
BUY
Number of Analysts
1
Last Close Price
4.07
Average target price
-
Annual profits - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| +40.34% | 8.62M | |
| -2.31% | 103B | |
| +0.56% | 95.28B | |
| +1.69% | 22.15B | |
| -17.37% | 21.02B | |
| -9.30% | 18.15B | |
| -41.01% | 16.74B | |
| -14.85% | 16.05B | |
| +3.21% | 13.68B | |
| +33.54% | 12.17B |
- Stock Market
- Equities
- XRTX Stock
